(VIANEWS) – Shares of Viking Therapeutics (NASDAQ: VKTX) slid by a staggering 33.07% in 21 sessions from $23.07 at 2023-06-05, to $15.44 at 15:08 EST on Tuesday, following the last session’s downward trend. NASDAQ is jumping 0.21% to $13,816.77, after two sequential sessions in a row of gains.
Viking Therapeutics’s last close was $15.44, 39.97% below its 52-week high of $25.72.
About Viking Therapeutics
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Viking Therapeutics has a trailing twelve months EPS of $-0.77.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -45.71%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Viking Therapeutics’s EBITDA is -56.81.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 17.4% and 4.8%, respectively.
More news about Viking Therapeutics (VKTX).
